Table V.
Comparison of clinical and radiographic response to CZP plus MTX and monotherapy.
| Authors (Ref.) | Groups | Disease duration (weeks) | ACR20 | ACR50 | ACR70 | mTTS (Mean) | DAS (Mean ± SD) |
|---|---|---|---|---|---|---|---|
| Smolen, et al (45) | CZP 200 mg + MTX | 24 | 57.3 | 32.5 | 15.9 | 0.2 | −2.27 (1.38) |
| CZP 400 mg + MTX | 57.6 | 32.5 | 10.6 | −0.4 | −2.46 (1.31) | ||
| PBO + MTX | 8.7 | 33.1 | 0.8 | 1.2 | −0.50 (1.05) | ||
| Keystone, et al (46) | CZP 200 mg | 24 | 58.8 | 37.1 | 21.4 | −3.3±1.3 | |
| CZP 400 mg + MTX | 60.8 | 39.9 | 20.6 | −3.4±1.4 | |||
| PBO + MTX | 13.6 | 7.6 | 3.0 | −2.4±1.3 | |||
| Fleischmann, et al (47) | CZP 400 mg | 24 | 45.4 | 22.7 | 5.5 | −1.5 | |
| PBO | 9.3 | 3.7 | 0.0 | −0.6 |
CZP, certolizumab pegol; MTX, methotrexate; ACR, American College of Rheumatology; DAS28, DAS in 28 joints; mTTS, modified total sharp score; PBO, placebo; SD, standard deviation.